These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
276 related items for PubMed ID: 26993628
1. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG. Respir Res; 2016 Mar 18; 17():29. PubMed ID: 26993628 [Abstract] [Full Text] [Related]
2. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. J Allergy Clin Immunol; 2009 Dec 18; 124(6):1210-6. PubMed ID: 19910033 [Abstract] [Full Text] [Related]
3. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE, Figliomeni M, Spector S. Allergy Asthma Proc; 2012 Dec 18; 33(5):377-85. PubMed ID: 23026179 [Abstract] [Full Text] [Related]
4. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Ann Intern Med; 2011 May 03; 154(9):573-82. PubMed ID: 21536936 [Abstract] [Full Text] [Related]
9. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Lancet Respir Med; 2016 Oct 03; 4(10):781-796. PubMed ID: 27616196 [Abstract] [Full Text] [Related]
10. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Curr Med Res Opin; 2010 Jun 03; 26(6):1285-93. PubMed ID: 20377320 [Abstract] [Full Text] [Related]
11. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Am J Respir Crit Care Med; 2013 Apr 15; 187(8):804-11. PubMed ID: 23471469 [Abstract] [Full Text] [Related]
15. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, O'Byrne PM. J Allergy Clin Immunol; 2016 Oct 15; 138(4):1051-1059. PubMed ID: 27185571 [Abstract] [Full Text] [Related]
20. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, Taam RA, Fayon M, Brouard J, Dubus JC, Siret D, Weiss L, Pouessel G, Beghin L, Just J. Eur Respir J; 2013 Nov 15; 42(5):1224-33. PubMed ID: 23520319 [Abstract] [Full Text] [Related] Page: [Next] [New Search]